Barcelona, Spain - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines, has started marketing XEMBIFY®, its 20% subcutaneous immunoglobulin, in Spain. This plasma medicine is indicated for treating primary immunodeficiencie.
June 26, 2023 Grifols begins European launch of XEMBIFY® in Spain to treat immunodeficiencies Print this news Download the press release Primary immunodeficiencies (PID) affect.
November 24, 2021 Grifols launches new home-care treatment service for patients with alpha-1 antitrypsin deficiency in Spain Print this news Download the press. | November 24, 2021